

=> b reg  
FILE 'REGISTRY' ENTERED AT 17:20:58 ON 17 SEP 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 SEP 2009 HIGHEST RN 1185221-67-3  
DICTIONARY FILE UPDATES: 16 SEP 2009 HIGHEST RN 1185221-67-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta 17  
L5 STR  
CC(C)(C)c1ccccc1Nc2ccccc2Cc3ccccc3Nc4ccccc4Nc5ccccc5Nc6ccccc6Nc7ccccc7Nc8ccccc8Nc9ccccc9Nc10ccccc10Nc11ccccc11Nc12ccccc12Nc13ccccc13Nc14ccccc14Nc15ccccc15N  
Hy~C~~C~~C~~C~~C~~N~~G1  
1 2 3 4 5 6 7  
G2 9  
10  
15 C C 11  
14 C C 12  
13

VAR G1=O/S  
VAR G2=AR/ID  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED  
ECOUNT IS E4 C E2 N AT 1

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE  
L7 74 SEA FILE=REGISTRY SSS FUL L5

100.0% PROCESSED 27415 ITERATIONS 74 ANSWERS  
SEARCH TIME: 00.00.02

=> b zcap  
FILE 'ZCAPPLUS' ENTERED AT 17:21:08 ON 17 SEP 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 17 Sep 2009 VOL 151 ISS 12  
FILE LAST UPDATED: 16 Sep 2009 (20090916/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPLus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.


=> d bib abs hitrn fhitstr l10 tot

L10 ANSWER 1 OF 1 ZCPLUS COPYRIGHT 2009 ACS ON STN  
 AN 2005:182646 ZCPLUS  
 DN 142:280227  
 TI Preparation of hydroxamates as matrix metalloproteinase inhibitors  
 IN US, Glaxo, Inc., Stephen John; Bombrun, Agnes  
 PA Vernasol Oxford Limited, UK; Laboratorios Serono S.A.  
 SO PCT Int. Appl. 89 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FNAN,LC

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-2005019194 A1	20050303	2004WO-GB0003558	20040818	
W: CN, CO, CR, CU, CZ, DE, DK, DM, ES, EC, EE, EG, ES, FI, FR, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TW, TR, TZ, VN, ZA, ZM, ZW				
RW: BM, GR, IE, LU, NL, PL, PT, SE, SG, SI, ZA, ZM, ZW				
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, TD, TG				

AU-2004066909 A1	20050303	2004AU-00266896	20040818	
CA-2536576 A1	20050303	2004CA-002536576	20040818	
EP-1660471 A1	20060531	2004EP-000768117	20040818	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PI, IE, SI, FI, RO, MK, CY, AL, TR, BY, EE, ES, PL, SK, HR				
JP-2007-134002-02-A	20070202	2006JP-0005624410	20060818	
CN-1320139 A	20070314	2004CN-080023748	20040818	
KR-2006037446 A	20060503	2006KR-000703187	20060216	
MX-2006001865 A	20060920	2006MX-000001865	20060216	
NO-2006001302 A	20060519	2006NO-00001302	20060322	
ZA-2006001359 A	20060519	2006ZA-000000238	20060322	
IN-200600997 A	20070615	2006IN-000000997	20060323	
US-20060281920 A1	20061214	2006US-00058433	20060808	

PRATI 2003GB-00019917 A 20030823  
 2003GB-00022022 A 20031210  
 2003GB-0003558 A 20031210  
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OS CASREACT 142:280227; MARPAT 142:280227  
 GI



AB Title compds. I (wherein Ar = (un)substituted (hetero)aryl or (hetero)cycloalkyl; R = H or (cyclo)alkyl; Alk = alkylene or alkenylene; R1 and R2 link together to form (un)substituted heterocycloalkyl rings which is optionally fused to (un)substituted (hetero)cycloalkyl rings; and

(Continued)  
 enantiomers, diastereoisomers, salts, hydrates or solvates thereof) were prepd. as inhibitors of matrix metalloproteinases. For example, II was synthesized starting from (2S)-hydroxyphenylacetic acid diisopropyl ester in several steps with >90% overall activity against MMP-9, MMP-12 and MMP-13 with IC50 values of <100 nM, <100 nM, >10000 nM, <100 nM, resp. II also showed 57% inhibition of IL2-induced peritoneal recruitment of lymphocytes at the dose of 3 mg/kg (vs. 76% inhibition by dexamethasone at 10 mg/kg). In general, are selective inhibitor of MMP-12 and MMP-9 relative to the other collagens and proteases. Therefore, and pharmaceutical compds. thereof are useful in the treatment or prophylaxis of diseases or conditions primarily mediated by MMP-12 and/or MMP-9, esp. inflammatory conditions, such as multiple sclerosis and fibrosis.

II 1044658-54-9  
 RL: PRDH (Prophetic)  
 (Preparation of hydroxamates as matrix metalloproteinase inhibitors)  
**847037-74-2P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847037-76-7P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847037-78-9P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847037-80-3P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847037-82-7P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847037-92-9P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847037-94-9P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847037-96-1P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847037-97-2P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-00-0P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-02-2P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-04-4P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-06-6P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-08-BP**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-19-1P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-23-7P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(3-methoxyphenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-26-0P**, 6-(4-(Benzodioxol-5-yl)methyl)piperazin-1-yl)hexanoic acid hydroxymamide  
**847038-28-1P**, 6-(4-(Benzodioxol-5-yl)methyl)piperazin-1-yl)hexanoic acid hydroxymamide  
**847038-34-0P**, 4-(4-(Benzodioxol-5-yl)methyl)piperazin-1-yl)hexanoic acid hydroxymamide  
**847038-41-1P**, 6-(4-(Benzodioxol-5-yl)methyl)piperazin-1-yl)hexanoic acid hydroxymamide  
**847038-44-2P**, 6-(4-(Benzodioxol-5-yl)methyl)piperazin-1-yl)hexanoic acid hydroxymamide  
**847038-46-3P**, 6-(4-(Benzodioxol-5-yl)methyl)piperazin-1-yl)hexanoic acid hydroxymamide  
**847038-48-6P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(4-trifluoromethyl)phenyl)sulfonyl]piperazin-1-yl)hexanoic acid hydroxymamide  
**847038-50-0P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(4-tolylsulfonyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-52-2P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(4-tolylsulfonyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-54-4P**, 6-(4-(5-Bromochien-2-yl)sulfonyl)piperazin-1-yl)hexanoic acid hydroxymamide  
**847038-54-4P**, 6-(4-(5-((Phenylsulfonyl)thien-2-yl)sulfonyl)piperazin-1-yl)hexanoic acid hydroxymamide  
**847038-55-5P**, 6-(4-(5-((Phenylsulfonyl)thien-2-yl)sulfonyl)piperazin-1-yl)hexanoic acid hydroxymamide  
**847038-56-6P**, 6-(4-(4-Acetoxyphenyl)sulfonyl)piperazin-1-yl)hexanoic acid hydroxymamide  
**847038-58-BP**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(4-methoxy-2,3,6-trimethylbenzyl)sulfonyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-59-2P**, 6-(4-Ethoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(4-methoxy-2,3,6-trimethylbenzyl)sulfonyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-62-4P**, 6-(4-Methoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(2-fluorophenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide

L10 ANSWER 1 OF 1 ZCPLUS COPYRIGHT 2009 ACS ON STN (Continued)  
**847038-64-6P**, 6-(4-Methoxyphe(nyl)-(2S)-hydroxy-(3R)-[(4-(pyridin-2-yl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-66-8P**, 6-(4-(Fluorophenyl)-(2S)-hydroxy-(3R)-[(4-(2-fluorophenyl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-68-0P**, 6-(4-(4-Fluorophenyl)-(2S)-hydroxy-(3R)-[(4-(pyridin-2-yl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-69-2P**, 6-(4-(4-Fluorophenyl)-(2S)-hydroxy-(3R)-[(4-(pyridin-2-yl)piperazin-1-yl)carbonyl]hexanoic acid hydroxymamide  
**847038-70-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-72-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-74-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-76-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-78-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-80-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-82-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-84-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-86-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-88-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-90-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-92-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-94-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-96-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-98-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-100-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-102-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-104-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-106-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-108-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-110-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-112-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-114-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-116-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-118-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-120-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-122-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-124-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-126-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-128-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-130-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-132-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-134-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-136-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-138-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-140-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-142-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-144-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-146-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-148-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-150-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-152-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-154-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-156-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-158-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-160-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-162-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-164-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-166-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-168-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-170-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-172-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-174-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-176-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-178-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-180-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-182-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-184-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-186-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-188-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-190-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-192-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-194-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-196-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-198-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-200-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-202-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-204-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-206-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-208-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-210-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-212-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-214-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-216-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-218-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-220-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-222-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-224-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-226-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-228-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-230-4P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-232-6P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-234-8P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-236-0P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-238-2P**, 6-(4-(4-Benzyl-(2S)-methyl)piperazin-1-yl)carbonyl-6-(4-(4-ethoxyphe(nyl)-(2S)-hydroxyhexanoic acid hydroxymamide  
**847038-240-4P**, 6-(4-(4-Benzyl-(2S)-methyl)p

10 / 568433

=> d bib abs hitstr l11 tot

L11 ANSWER 1 OF 1 ZCPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:101557 ZCPLUS  
 DN 144:171021  
 TI Preparation of piperazine and related N-hydroxy succinic acid diamide derivs. as metalloproteinase inhibitors with therapeutic uses  
 IN Swinnen, Dominique; Bonbrun, Agnes; Gonzalez, Jerome; Crosignani, Stefano;  
 Gerber, Patrick; Jorand-Lebrun, Catherine  
 PA Applied Research Systems Ars Holding N.V., Neth. Antilles  
 SO PCT Int. Appl., 203 pp.  
 COOP. PIXXD2

DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-2006010751	A1	20060202	20050-BP0052616	20050725
W1 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MN, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NL, NO, NC, PG, PH, PL, PT, RO, RU, SC, SE, SB, SG, SK, SL, SM, SZ, T1, TM, TN, TR, TT, TZ, UA, US, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, GM, KE, LS, MM, MW, NA, SD, SL, SZ, TZ, US, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH				

AU-2005266313 A1 20060202 2005AU-000266313 20050725

CA---257093 A1 20060202 2005CA-00257093 20050725

EP---1771421 A1 20090421 2005EP-000772035 20050725

EP---1771421 R: A1, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
BA, HR, MK, YU

CN---2591113 A 20070627 2005CN-000252006 20050725

JP---2008507575 T 20080313 2007JP-000523074 20050725

BR---2005013878 A 20080520 2005BR-000013878 20050725

ZA---200700744 A 20080827 2007ZA-00000744 20050725

AT---430133 T 20090515 2005AT-0000072035 20050725

IN---20060060 A 20080515 2005IN-0000060 20050725

MX---2007001022 A 20070412 2007MX-000001022 20070125

US---20080021028 A1 20080124 2007US-000572761 20070126

KR---2007046873 A 20070503 2007KR-000704004 20070220

NO---200700934 A 20070426 2007NO-000000934 20070221

PRAI 200600000074 A 20070426 2007NO-000000934 20070221

2004US-00591111P P 20040726 20050131

2005EP-000100641 P 20050201

2005US-00648924P P 20050201

2005WO-EP0053616 W 20050725

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 344:171021

GI

GI

L11 ANSWER 1 OF 1 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)

874646-87-4P, (2S,3R)-3-[4-(6-Chloropyridin-2-yl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-88-5P, (2S,3R)-3-[4-(5-Chloropyridin-2-yl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-89-6P, (2S,3R)-3-[4-(4-Chloro-2-fluorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-92-1P, (2S,3R)-3-[4-(2-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-93-2P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-94-3P, (2S,3R)-6-(4-Ethoxyphenyl)hexanamide

874646-97-4P, (2S,3R)-3-[4-(3-Dichlorophenoxy-1-yl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-98-5P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[(4-(2-methoxyphenyl)piperazin-1-yl)carbonyl]hexanamide

874646-99-6P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[(4-(2-methoxyphenyl)piperazin-1-yl)carbonyl]-N-hydroxyhexanamide

874646-99-8P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[(4-(2-methoxyphenyl)piperazin-1-yl)carbonyl]-N-hydroxyhexanamide

874646-10-0P, (2S,3R)-3-[4-(2-Cyanoethyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-1P, (2S,3R)-3-[4-(2-Fluoromethyl)piperazin-1-yl]carbonyl-N-hydroxy-2-hydroxy-6-[(4-(trifluoromethyl)phenyl)hexanamide

874646-10-2P, (2S,3R)-3-[4-(6-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-3P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-4P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-5P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-6P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-7P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-8P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-9P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-10P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-11P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-12P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-13P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-14P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-15P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-16P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-17P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-18P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-19P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-20P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-21P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-22P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-23P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-24P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-25P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-26P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-27P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-28P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-29P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-30P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-31P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-32P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-33P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-34P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-35P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-36P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-37P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-38P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-39P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-40P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-41P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-42P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-43P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-44P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-45P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-46P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-47P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-48P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-49P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-50P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-51P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-52P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-53P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-54P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-55P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-56P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-57P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-58P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-59P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-60P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-61P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-62P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-63P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-64P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-65P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-66P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-67P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-68P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-69P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-70P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-71P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-72P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-73P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-74P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-75P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide


874646-10-76P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-77P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide

874646-10-78P, (2S,3R)-3-[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide


L11 ANSWER 1 OF 1 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 CN 1-Piperazinebutanamide,  $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-4-[5-(trifluoromethyl)-2-pyridinyl]-, (as,br)- (CA INDEX NAME)

Absolute stereochemistry.




RN 874646-85-2 ZCPLUS  
 CN 1-Piperazinebutanamide, 4-(5-cyano-2-pyridinyl)- $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-, (as,br)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-86-3 ZCPLUS  
 CN 1-Piperazinebutanamide,  $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy-4-(6-methyl-2-pyridinyl)- $\gamma$ -oxo-, (as,br)- (CA INDEX NAME)


Absolute stereochemistry.



RN 874646-87-4 ZCPLUS  
 CN 1-Piperazinebutanamide, 4-(6-chloro-2-pyridinyl)- $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-, (as,br)- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 874646-88-5 ZCPLUS  
 CN 1-Piperazinebutanamide,  $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy-4-(2-fluorophenyl)- $\gamma$ -oxo-, (as,br)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-89-6 ZCPLUS  
 CN 1-Piperazinebutanamide, 4-(2-chlorophenyl)- $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-, (as,br)- (CA INDEX NAME)

Absolute stereochemistry.




RN 874646-90-7 ZCPLUS  
 CN 1-Piperazinebutanamide,  $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-4-(2-methoxyphenyl)-, (as,br)- (CA INDEX NAME)

Absolute stereochemistry.

RN 874646-91-8 ZCPLUS  
 CN 1-Piperazinebutanamide, 4-(3,5-dichloro-4-pyridinyl)- $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-, (as,br)- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 874646-92-1 ZCPLUS  
 CN 1-Piperazinebutanamide, 4-(3-(4-ethoxyphenyl)propyl)- $\beta$ -(3-(4-pyridinyl))-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-, (as,br)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-93-2 ZCPLUS  
 CN 1-Piperazinebutanamide, 4-(2-pyridinyl)- $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-, (as,br)- (CA INDEX NAME)


Absolute stereochemistry.



RN 874646-94-3 ZCPLUS  
 CN 1-Piperazinebutanamide,  $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-4-(4-pyridinyl)-, (as,br)- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 1 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 874646-95-4 ZCPLUS  
 CN 1-Piperazinebutanamide, 4-(3,5-dichloro-4-pyridinyl)- $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-4-(4-pyridinyl)-, (as,br)- (CA INDEX NAME)

Absolute stereochemistry.




RN 874646-96-5 ZCPLUS  
 CN 1-Piperazinebutanamide,  $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-4-(2-pyrazinyl)-, (as,br)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-97-6 ZCPLUS  
 CN 1-Piperazinebutanamide, 4-(4-chlorophenyl)- $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-, (as,br)- (CA INDEX NAME)

Absolute stereochemistry.




RN 874646-98-7 ZCPLUS  
 CN 1-Piperazinebutanamide,  $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-4-(2-pyrazinyl)-, (as,br)- (CA INDEX NAME)

Absolute stereochemistry.

RN 874646-99-8 ZCPLUS  
 CN 1-Piperazinebutanamide,  $\beta$ -(3-(4-ethoxyphenyl)propyl)-N, $\alpha$ -dihydroxy- $\gamma$ -oxo-4-(4-morpholinyl)ethyl-, (as,br)- (CA INDEX NAME)


L11 ANSWER 1 OF 1 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)

Absolute stereochemistry.




RN 874647-00-4 ZCPLUS  
CN 1-Piperazinebutanamide, 4-(2-cyanophenyl)-β-[3-(4-ethoxyphe-  
nyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 874647-01-5 ZCPLUS  
CN 1-Piperazinebutanamide, 4-(2-fluorophenyl)-N,α-dihydroxy-γ-oxo-  
β-[3-(4-(trifluoromethoxy)phenyl)propyl]-, (αS,βR)- (CA  
INDEX NAME)

Absolute stereochemistry.




RN 874647-02-6 ZCPLUS  
CN 1-Piperazinebutanamide, 4-(6-chloro-2-pyridinyl)-N,α-dihydroxy-  
γ-oxo-β-[3-(4-(trifluoromethoxy)phenyl)propyl]-,  
(αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 1 OF 1 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)

Absolute stereochemistry.




RN 874647-04-8 ZCPLUS  
CN 1-Piperazinebutanamide, N,α-dihydroxy-γ-oxo-4-(2-pyridinyl)-  
β-[3-(4-(trifluoromethoxy)phenyl)propyl]-, (αS,βR)- (CA  
INDEX NAME)

Absolute stereochemistry.



RN 874647-38-8 ZCPLUS  
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphe-  
nyl)propyl]-N,α-dihydroxy-γ-oxo-4-[2-(2-thienyl)ethyl]-, (αS,βR)- (CA  
INDEX NAME)

Absolute stereochemistry.




RN 874647-40-2 ZCPLUS  
CN 1-Piperazinebutanamide, 4-cyclononyl-β-[3-(4-ethoxyphe-  
nyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 874647-54-8 ZCPLUS  
CN 1-Piperazinebutanamide, N,α-dihydroxy-γ-oxo-β-  
(phenylmethoxy)-4-[4-(trifluoromethoxy)phenyl]-, (αR,βS)- (CA  
INDEX NAME)

Absolute stereochemistry.



RN 874647-55-9 ZCPLUS  
CN 1-Piperazinebutanamide, N,α-dihydroxy-2-methyl-γ-oxo-β-  
(phenylmethoxy)-4-[4-(trifluoromethoxy)phenyl]-, (αS,βS,2R)- (CA  
INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his  
(FILE 'HOME' ENTERED AT 17:10:30 ON 17 SEP 2009)  
FILE 'ZCPLUS' ENTERED AT 17:10:45 ON 17 SEP 2009  
L1 1 US20060281920/PN  
FILE 'REGISTRY' ENTERED AT 17:11:03 ON 17 SEP 2009  
FILE 'ZCPLUS' ENTERED AT 17:11:03 ON 17 SEP 2009  
L2 TRA L1 1- RN : 118 TERMS  
FILE 'REGISTRY' ENTERED AT 17:11:03 ON 17 SEP 2009  
L3 118 SEA L2  
L4 57 L3 AND NC2NC2/ES  
L5 STR  
L6 4 L5  
L7 74 L5 FULL  
SAV TEM J433C1RCE/A L7  
L8 45 L7 AND L3  
L9 29 L7 NOT L8  
FILE 'ZCPLUS' ENTERED AT 17:20:07 ON 17 SEP 2009  
L10 1 L8  
L11 1 L9

=>